Abstract: Described herein are methods of promoting engraftment of a cell transplant and methods of killing hematopoietic stem cells by administering a population of T cells, NK cells or cytotoxic immune effector cells comprising a cell-surface receptor for a stem cell-specific antigen. Also described herein is a composition comprising T cells, NK cells or cytotoxic immune effector cells genetically modified to encode a cell-surface receptor for a stem cell-specific antigen.

Abstract: The present invention provides recombinant nucleic acid expression cassetie and helper dependent adenovirus, where the expression cassettes utilize a miRNA based system for controlling expression of nucleases in helper dependent adenoviral viral producer cells, thus permitting production and use for in in vivo gene editing in CD34+ cells.

Abstract: The present invention provides for novel chimeric Ad-vectors carrying transgene, or portions of transgenes for stable and efficient gene transfer into diverse cell types or tissues in a CAR- and/or ???3/5-independent manner. Also provided are methods for producing such vectors and the use thereof for gene therapy to target a specific cell type or tissue.

Abstract: The invention is directed to fetal globin inducing factor (FGIF), and to nucleic acids encoding FGIF. FGIF controls the expression of fetal globin gene products. An FGIF polypeptide is shown in FIG. 3 and nucleotide sequences that encode FGIF polypeptides are shown in FIGS. 1 and 2. The invention is also directed to therapeutic methods employing FGIF polypeptides, encoding nucleic acids and functional fragments thereof for the treatment of globin disorders and to methods for screening compounds that modulate fetal globin gene expression as well as compounds identified by these methods.

Abstract: The invention relates to in vivo peripheralization of CD34.sup.+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.

Abstract: The invention provides methods for peripheralizing CD34.sup.+ cells, including hematopoietic stem cells. In a first aspect, the method comprises the step of administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells. In a second aspect, the method comprises administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells and administering a stimulating agent of CD34.sup.+ cell proliferation in vivo. The method according to the invention is useful in the treatment of cancer or AIDS, and in gene therapy.

Abstract: The invention provides methods for peripheralizing CD 34.sup.+ cells, including hematopoietic stem cells. In a first aspect, the method comprises the step of administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells. In a second aspect, the method comprises administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells and administering a stimulating agent of CD34.sup.+ cell proliferation in vivo. The method according to the invention is useful in the treatment of cancer or AIDS, and in gene therapy.

Abstract: The invention relates to in vivo peripheralization of CD34+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.